Tag: Amneal
-
Amneal Pharmaceuticals (AMRX): By Most Measures, A Fundamentally Undervalued Company
ariya j/iStock via Getty Images Investment Overview I last covered Amneal Pharmaceuticals (NYSE:AMRX) for Seeking Alpha in a post published in March 2022. I gave the stock a “Buy” rating – at the time, Amneal stock traded at $4 per share, and although it had sunk as low as $1.3 per share by late May…